Back to News
Market Impact: 0.35

JNJ Factor-Based Stock Analysis

JNJNDAQ
Company FundamentalsAnalyst InsightsHealthcare & BiotechMarket Technicals & FlowsInvestor Sentiment & Positioning
JNJ Factor-Based Stock Analysis

Validea's guru fundamental report indicates that Johnson & Johnson (JNJ) receives a rating of 87% based on their Multi-Factor Investor model, which is based on the strategy of Pim van Vliet and seeks low volatility stocks with strong momentum and high net payout yields; the stock passes tests for market cap and standard deviation, but is neutral on twelve minus one momentum and net payout yield. According to Validea, a score of 80% or above typically indicates that the strategy has some interest in the stock and a score above 90% typically indicates strong interest.

Analysis

Johnson & Johnson (JNJ) has garnered an 87% rating from Validea's Multi-Factor Investor model, which is predicated on Pim van Vliet's strategy targeting low volatility stocks exhibiting strong momentum and high net payout yields. This score signifies that the strategy has "some interest" in JNJ, a large-cap growth stock within the Biotechnology & Drugs sector. The analysis reveals that JNJ satisfies the model's criteria for market capitalization and standard deviation, aligning with the desired low volatility characteristic. However, JNJ's performance is 'NEUTRAL' concerning 'twelve minus one momentum' and 'net payout yield,' indicating it does not fully meet the strategy's ideal profile for these specific factors. Notably, a detailed table within the report outlining the strategy's tests assigns JNJ a 'FINAL RANK: FAIL', which introduces a significant point of consideration when weighed against the relatively high 87% overall model score.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo

Market Sentiment

Overall Sentiment

strongly positive

Sentiment Score

0.65

Ticker Sentiment

JNJ0.75
NDAQ0.00

Key Decisions for Investors

  • Investors may find Johnson & Johnson suitable for portfolios emphasizing low-volatility factors, given its 87% model rating and positive performance on market capitalization and standard deviation tests within the Pim van Vliet strategy.
  • Careful consideration should be given to Johnson & Johnson's 'Neutral' ratings for 'twelve minus one momentum' and 'net payout yield', as these indicate a deviation from the ideal characteristics sought by the multi-factor strategy.
  • The 'FINAL RANK: FAIL' in the detailed strategy checklist, contrasting with the overall 87% model score, necessitates further due diligence to understand the specific underperforming criteria and reconcile these mixed signals before making investment decisions.